Neurocrine Rare Disease Drug Faces Post-Approval Safety Scrutiny — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Neurocrine Biosciences is at the center of a STAT+ analysis weighing a rare disease drug's post-approval benefit-risk profile, originally greenlit on modestly effective results from a small clinical trial with manageable side effects
- After approval, prescribing physicians reported a small number of patient deaths, even though no deaths had occurred during the clinical trial that supported the drug's authorization
- Serious side effects rose dramatically in real-world use compared with the trial characterization, with some episodes so severe that patients required hospitalization
- The article frames the drug's real-world safety profile as appearing worse than what was characterized in the small pre-approval clinical trial, raising questions about how regulators initially weighed benefit against risk
Why it matters: The preview describes a fundamental regulatory tension: small trials in devastating rare diseases may clear drugs that look tolerable at approval but surface serious harm under wider use. For Neurocrine, prescribers, and rare disease patients, the gap between trial-stage safety data and post-market experience is the entire crux of the article's benefit-risk reassessment.
Ask SkimNews
